Fertomid 100 mg Laboratory Research Overview
Fertomid 100 mg is a clomiphene citrate research compound manufactured by Cipla for in-vitro laboratory studies. As a selective estrogen receptor modulator (SERM), this compound serves as a valuable research tool for scientists investigating estrogen receptor interactions and gonadotropin pathways. The standardised 100 mg formulation provides consistent dosing parameters for experimental protocols examining SERM mechanisms. Research teams at Stroid UK Shop utilise this compound to evaluate tissue-selective estrogen receptor antagonism in controlled laboratory conditions.
Molecular Research Applications
Laboratory investigations with Fertomid focus on clomiphene citrate’s dual isomeric composition, examining both enclomiphene and zuclomiphene activities in cellular models. Research protocols commonly evaluate hypothalamic-pituitary responses, studying how SERM compounds influence gonadotropin-releasing hormone pathways. Scientists analyse estrogen receptor binding affinity across different tissue types, comparing antagonistic effects in hypothalamic tissue versus agonistic properties in bone and liver models. Advanced research programmes incorporate clomiphene citrate compounds alongside studies involving selective androgen receptor modulators and peptide research compounds to examine complex hormonal interactions.
Technical Specifications
| Active Compound | Clomiphene Citrate |
|---|---|
| Concentration | 100 mg per tablet |
| Manufacturer | Cipla |
| CAS Number | 50-41-9 (clomiphene base) |
| Molecular Formula | C₂₆H₂₈ClNO·C₆H₈O₇ |
| Storage Requirements | Room temperature, dry conditions |
Research Compliance Statement
Fertomid 100 mg is supplied exclusively for in-vitro research purposes and laboratory analysis. This product is not intended for human consumption, clinical use, or any application outside controlled research environments. Research teams must maintain appropriate laboratory protocols and documentation when conducting studies with this SERM compound. All investigations should comply with institutional research guidelines and safety protocols for handling pharmaceutical-grade research materials.
